Representatives from AstraZeneca and its global biologics research and development division, MedImmune, recently presented on their oncology research at the 2015 European Cancer Congress (ECC) in Vienna.
The representatives gave 19 oral and poster presentations on treatments for lung cancers and ovarian cancers, advances in biomarker research, oncology strategy, cancer biology and research and drug development.
AstraZeneca plans to create six new cancer drugs by 2020, and the company is reportedly on track to achieve that goal.
"Data published at ECC 2015 confirm the strength and rapid progress of our development plan in oncology. Our large and growing dataset for AZD9291 is a great example of this, as it highlights the robustness and consistency of the results we are seeing across a broad population of pre-treated non-small cell lung cancer patients," AstraZeneca Global Product Strategy for Oncology VP Mondher Mahjoubi told Patient Daily.
MedImmune is based in Gaithersburg, Md., and AstraZeneca operates in more than 100 countries.
